Laurus Labs Share Price Target From 2025 to 2030: A major player in the healthcare sector, Laurus Labs operates within the Drug Manufacturers – Specialty & Generic industry. It is listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE).
This comprehensive post examines Laurus Labs’ stock price forecast for 2025, 2026, and up to 2030. Long-term forecasts are made using various technical analysis approaches to predict targets up to 2030.
To project Laurus Labs’ share price up to 2030, we use a machine learning approach leveraging historical performance data. Laurus Labs Limited, known for its significant presence in the Indian stock market, has exhibited various trends over the years.
This section explores Laurus Labs’ current market position, growth trajectory, and the potential impact of external market factors on its price performance up to 2030.
Laurus Labs Company Overview
| Company Name | Laurus Labs Ltd. |
| Founded | 2005 |
| Headquarters | Hyderabad |
| Industry | Pharmaceutical and Biotechnology |
| Chairman | Ravindranath Kancherla |
| Stock Exchange Listing | NSE & BSE |
| Official Website | lauruslabs.com |
Laurus Labs Fundamental Analysis
| Metric | Value |
|---|---|
| Market Cap | ₹4,58,107.91 Cr. |
| ROE | 20.74% |
| ROCE | 12.29% |
| P/E | 29.38 |
| P/B | 5.78 |
| Div. Yield | 0.49% |
| Book Value | ₹1,277.64 |
| Face Value | ₹2 |
| EPS (TTM) | ₹251.54 |
| 52 Week High | ₹7,830 |
| 52 Week Low | ₹6,187.80 |
Also Read: Transrail Lighting Share Price Target
Laurus Labs Financials
Income Statement
| (INR) | 2024 | Y/Y change |
|---|---|---|
| Revenue | 50.41B | -16.55% |
| Operating expense | 21.06B | 11.67% |
| Net income | 1.61B | -79.68% |
| Net profit margin | 3.18 | -75.69% |
| Earnings per share | 2.97 | -79.71% |
| EBITDA | 7.63B | -52.50% |
| Effective tax rate | 29.58% | — |
Balance Sheet
| (INR) | 2024 | Y/Y change |
|---|---|---|
| Cash and short-term investments | 1.42B | 192.30% |
| Total assets | 83.87B | 9.49% |
| Total liabilities | 42.71B | 18.27% |
| Total equity | 41.16B | — |
| Shares outstanding | 538.97M | — |
| Price to book | 8.02 | — |
| Return on assets | 3.08% | — |
| Return on capital | 3.87% | — |
Cash Flow
| (INR) | 2024 | Y/Y change |
|---|---|---|
| Net income | 1.61B | -79.68% |
| Cash from operations | 6.66B | -33.02% |
| Cash from investing | -8.22B | 17.43% |
| Cash from financing | 2.50B | 1,037.80% |
| Net change in cash | 932.70M | 414.25% |
| Free cash flow | -2.44B | 38.18% |
Also Read: Max Healthcare Share Price Target
Laurus Labs Share Price Target From 2025 to 2030
| Year | Target Price |
|---|---|
| Laurus Labs Share Price Target 2025 | ₹720 |
| Laurus Labs Share Price Target 2026 | ₹840 |
| Laurus Labs Share Price Target 2027 | ₹980 |
| Laurus Labs Share Price Target 2028 | ₹1100 |
| Laurus Labs Share Price Target 2029 | ₹1270 |
| Laurus Labs Share Price Target 2030 | ₹1410 |
Laurus Labs Target Price For 2025: ₹720
The share price target for Laurus Labs in 2025 is set at 720 INR, reflecting significant growth from 2024. This growth is driven by the company’s strategic initiatives and market expansion. By focusing on therapeutic areas such as anti-retroviral drugs and oncology, Laurus Labs is well-positioned for strong performance in upcoming years. With a P/E ratio of 210.8, investors are optimistic about the company’s future, expecting higher growth to support a rising share price.
Laurus Labs Target Price For 2026: ₹840
Looking at 2026, the share price target for Laurus Labs is projected to reach 840 INR. This expected growth is supported by a consistent track record of operating profit and revenue growth. The company’s focus on innovative treatments for hepatitis C and cancer, as well as its expansion into international markets, will drive continued growth and contribute to achieving this goal.
Laurus Labs Target Price For 2027: ₹980
In 2027, the share price target for Laurus Labs is projected to reach 980 INR. As the company strengthens its market position and expands its footprint, it will continue to see growth in key areas including oncology and anti-retroviral therapies. This target reflects Laurus Labs’ ability to gain market share in these high-demand therapeutic areas, thereby increasing its valuation even further.
Laurus Labs Target Price For 2028: ₹1100
The share price target for Laurus Labs in 2028 is set at 1100 INR, reflecting continued progress in expanding its active pharmaceutical ingredients (API) business and entering new therapeutic areas. As Laurus Labs strengthens its market presence, its revenue growth will support a strong increase in the share price, reaching this key target by 2028.
Laurus Labs Target Price For 2029: ₹1270
The share price target for Laurus Labs in 2029 is forecast at 1270 INR, marking another milestone in its journey towards becoming a leader in the pharmaceutical industry. By 2029, Laurus Labs will have increased its market dominance, particularly in the oncology and HIV drug segments, with ongoing research and development fuelling this growth.
Laurus Labs Target Price For 2030: ₹1410
The share price target for Laurus Labs in 2030 is forecast at 1410 INR, indicating a long-term upward trajectory as the company continues to scale its operations globally. Laurus Labs’ strategic focus on high-growth therapeutic areas and its expansion into new global markets will support this steady increase in share price, making it an attractive option for long-term investors.
Laurus Labs Shareholding Pattern
- Retail & Other: 33.69%
- Promoters: 27.18%
- Foreign Institutions: 26.08%
- Mutual Funds: 8.25%
- Other Domestic Institutions: 4.80%
Also Read: KPI Green Energy Share Price Target
Laurus Labs Competitors/Peer Companies
- Piramal Pharma
- J. B. Chemicals and Pharmaceuticals Ltd. (JBCPL)
- Suven Pharmaceuticals Ltd.
- Emcure Pharmaceuticals Ltd.
- Wockhardt Ltd.
- Natco Pharma Ltd.
- Concord Biotech Ltd.
- Granules India Ltd.
- Alivus Life Sciences Ltd.
- Blue Jet Healthcare Ltd.
Also Read: IFCI Share Price Target
To connect with us, click on any of the given social media buttons.
FAQs
-
Is Laurus Labs a good buy for long term?
Yes.
-
Is Laurus Labs debt free?
No.
-
Is Laurus a MNC company?
Yes.
Disclaimer: The information in this blog is for educational purposes only, and the targets mentioned in it are given as suggestions by market analysts. Therefore, before investing your money in any company, it is mandatory to get complete information about the company and consult your financial advisor.
